Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 7/20 | 0.52 |
| ▸ | KDR | P35968 | 4/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL371888 | 0.89 | PDGFRA (0.60) | METKDRPDGFRALMNAMAPT | |
| SCHEMBL30106564 | 0.89 | PDGFRA (0.60) | METKDRPDGFRALMNAMAPT | |
| SCHEMBL1895559 | 0.87 | PDGFRA (0.65) | METKDRPDGFRAFGFR2 | |
| SCHEMBL4483017 | 0.84 | MET (0.55) | METKDRPDGFRA | |
| SCHEMBL371803 | 0.84 | MET (0.55) | METKDRPDGFRA | |
| SCHEMBL30713842 | 0.84 | MET (0.55) | METKDRPDGFRA | |
| SCHEMBL25233743 | 0.83 | KDR (0.48) | METKDRPDGFRA | |
| SCHEMBL30465509 | 0.83 | KDR (0.48) | METKDRPDGFRA | |
| SCHEMBL15338440 | 0.82 | PDGFRA (0.48) | METKDRPDGFRALMNAMAPT | |
| SCHEMBL3913550 | 0.81 | PDGFRA (0.53) | METKDRPDGFRALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | disclosed |
| EP-2032538-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | TK1, ABL1, ROR1 | MET 563/4885KDR 498/4885PDGFRA 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.